SCHEMBL16740339

SCHEMBL16740339

Cc1nc2cc(F)c(F)cc2n1-c1cncc(Nc2ccc(C(F)(F)F)nc2)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 8/20 0.43
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
IDO1 P14902 2/20 0.37
BUB1 O43683 1/20 0.35
TGFBR1 P36897 2/20 0.35
BACE2 Q9Y5Z0 1/20 0.34
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
MTOR P42345 1/20 0.33
BRAF P15056 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
MT-CO1 P00395 1/20 0.32
MT-CO2 P00403 1/20 0.32
EDNRA P25101 1/20 0.32
OPRM1 P35372 1/20 0.32
HTR2B P41595 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740405 0.90 BMI1 (0.55) BMI1ABL1BCRTGFBR1PIK3CD
SCHEMBL16740207 0.90 BMI1 (0.46) BMI1ABL1BCRTGFBR1BACE2
SCHEMBL29820520 0.87 BMI1 (0.55) BMI1ABL1BCRPIK3CAKCNH2
SCHEMBL16747858 0.87 BMI1 (0.55) BMI1ABL1BCRPIK3CAKCNH2
SCHEMBL16739862 0.86 BMI1 (0.52) BMI1ABL1BCR
SCHEMBL16739691 0.86 BMI1 (0.39) BMI1BUB1BACE2PIK3CDPIK3CA
SCHEMBL16747809 0.85 BMI1 (0.42) BMI1BUB1KCNH2
SCHEMBL16739727 0.84 BMI1 (0.45) BMI1BUB1PIK3CDPIK3CAMTOR
SCHEMBL16739582 0.82 KCNH2 (0.41) BMI1BUB1PIK3CDPIK3CAMTOR
SCHEMBL16740062 0.82 KCNH2 (0.50) BMI1ABL1BCRBRAFKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US claimed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US claimed
EP-3071553-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC Therapeutics, Inc. (US) 2016-09-28 EP claimed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO claimed
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885ABL1 1564/4885BCR 470/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B BMI1 1/4885ABL1 1564/4885BCR 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.